Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation
- 21 May 2012
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 38 (1), 44-46
- https://doi.org/10.1111/j.1365-2230.2012.04375.x
Abstract
Pyoderma gangrenosum (PG) commonly occurs in association with various haematological and inflammatory disorders. We report a new association, a Janus kinase (JAK)2 mutation, in a 63-year-old patient with PG. We hypothesise that PG occurs by direct activation of JAK along with signal transducers and activators of transcription (STAT), a common mechanism involved in the pathogenesis of inflammatory and haematological diseasesKeywords
This publication has 5 references indexed in Scilit:
- Targeting myeloproliferative neoplasms with JAK inhibitorsCurrent Opinion in Hematology, 2011
- Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand populationMutation Research - Reviews in Mutation Research, 2010
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- The JAK/STAT signaling pathwayJournal of Cell Science, 2004
- Bullous pyoderma gangrenosum after granulocyte colony-stimulating factor treatmentCancer, 1991